Investigational Studies

Shares of Synthetics Biologics, Inc. (NYSEMKT:SYN) added 3.59% by the end of trading session at $0.86. For the current quarter, the 5 brokerage firms issuing adjusted earnings per share outlook have a consensus forecast of -$0.08/share, which would compare with -$0.12 in the year-ago quarter. The net percentage change is -65.52% over the last 12 […]

by

[ACCESSWIRE] COSTA MESA, CA / ACCESSWIRE / December 20, 2016 / NEMUS Bioscience, Inc. (OTCQB: NMUS) announced it has signed a definitive license agreement for rights to Teewinot Life Sciences Corp.’s patented biosynthetic technology to produce NEMUS’ proprietary cannabinoid molecules. “Nemus is anticipating an era of hypergrowth in the pharmaceuticalized cannabinoid space and we believe […]

by

[ACCESSWIRE] COSTA MESA, CA / ACCESSWIRE / December 20, 2016 / NEMUS Bioscience, Inc. (OTCQB: NMUS) announced it has signed a definitive license agreement for rights to Teewinot Life Sciences Corp.’s patented biosynthetic technology to produce NEMUS’ proprietary cannabinoid molecules. “Nemus is anticipating an era of hypergrowth in the pharmaceuticalized cannabinoid space and we believe […]

by

British-based GW Pharmaceuticals announced positive Phase 3 study results of its drug Epidiolex for two treatment-resistant forms of epilepsy, at the 70th Annual Meeting of the American Epilepsy Society in Houston. Epidiolex is an oral formulation of cannabidiol (or CBD), one of 500 compounds found in cannabis.  Unlike the well-known compound, tetrahydrocannabinol (THC), CBD does not have a […]

by

GW Pharmaceuticals recently presented positive results from two Phase 3 clinical trials evaluating its lead cannabidiol therapeutic candidate, Epidiolex, in patients with lennox-gastaut syndrome (LGS) and Dravet syndrome (DS), two treatment-resistant epilepsy syndromes. The presentations took place during the American Epilepsy Society (AES) Annual Meeting in Houston, Texas Dec. 2-6. Epidiolex is an oral formulation of pure […]

by

British-based GW Pharmaceuticals announced positive Phase 3 study results of its drug Epidiolex for two treatment-resistant forms of epilepsy, at the 70th Annual Meeting of the American Epilepsy Society in Houston. Epidiolex is an oral formulation of cannabidiol (or CBD), one of 500 compounds found in cannabis.  Unlike the well-known compound, tetrahydrocannabinol (THC), CBD does […]

by

– Three Positive Phase 3 Epidiolex clinical trials reported in 2016 –– NDA submission and launch preparation on track –– Conference call today at 8:00 a.m. EST – LONDON, Dec. 05, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel […]

by